1179 related articles for article (PubMed ID: 23313382)
1. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
2. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
3. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
4. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure.
Henderson SJ; Xia J; Wu H; Stafford AR; Leslie BA; Fredenburgh JC; Weitz DA; Weitz JI
Thromb Haemost; 2016 Mar; 115(3):533-42. PubMed ID: 26489782
[TBL] [Abstract][Full Text] [Related]
5. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
8. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
Gronostaj K; Richter P; Nowak W; Undas A
Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
[TBL] [Abstract][Full Text] [Related]
9. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
10. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Wolzt M; Gouya G; Kapiotis S; Becka M; Mueck W; Kubitza D
Thromb Res; 2013 Aug; 132(2):240-7. PubMed ID: 23786894
[TBL] [Abstract][Full Text] [Related]
11. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
Reed GL; Matsueda GR; Haber E
Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
[TBL] [Abstract][Full Text] [Related]
12. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
13. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
14. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
[TBL] [Abstract][Full Text] [Related]
15. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.
Siudut J; Grela M; Wypasek E; Plens K; Undas A
J Thromb Haemost; 2016 Apr; 14(4):784-93. PubMed ID: 26786481
[TBL] [Abstract][Full Text] [Related]
16. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
17. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
Kobbervig C; Williams E
Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253
[TBL] [Abstract][Full Text] [Related]
18. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
[TBL] [Abstract][Full Text] [Related]
19. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
[TBL] [Abstract][Full Text] [Related]
20. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity.
Varin R; Mirshahi S; Mirshahi P; Kierzek G; Sebaoun D; Mishal Z; Vannier JP; Yvonne Borg J; Simoneau G; Soria C; Soria J
Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]